P952 Left ventricle ejection fraction and global longitudinal strain values in lymphoma patients previously treated with anthracycline-based chemotherapy. (17th January 2020)

• Record Type: Journal Article
• Authors: Codina, M; Ramirez-Escudero Ugalde, G; Manzanal Rey, A; Garcia Ibarrondo, N; Asla Ormaza, C; Lambarri Izaguirre, A; Candida Urizar, R; Ugedo Alzaga, K; Castellanos Alcalde, M; Arregui Lopez, A; Marquez Navarro, J A; Uriarte Elguezabal, J; Archocha Torres, M F; Ormaetxe Merodio, J; Ruiz Gomez, L
• Is Part Of: European heart journal. Volume 21(2020)Supplement 1
• Publication Date: 2020-01-17
• Subjects: Cardiovascular system -- Imaging -- Periodicals; Heart -- Imaging -- Periodicals; 616.10754
• DOI: 10.1093/ehjci/jez319.585
• Languages: English
• ISSNs: 2047-2404

Abstract

Abstract: Anthracyclines (anth) are potent antineoplasic agents, although, their efficacy is limited by cardiotoxicity. Most lymphoid malignancies tend to recur and commonly require anthracycline-based chemotherapy (anth-bch) re-treatment. Our aim is to compare the pretreatment left ventricle ejection fraction (lvef) and global longitudinal strain (gls) between patients (pts) with new diagnosis of lymphoma (lym) and pts with lym recurrence that were treated previously with anth-bch. Among pts referred to assess lvef and gls prior to start ttm, lym patients were selected and divided in two groups: pts with recurrent lymp previously treated with anth and pts with new diagnosis of lymp. Patients data, lvef and gls values were collected retrospectively. 96 pts data were analyzed (see table): 23 pts (24%) with previous anth ttm and 73 newly diagnosed pts. No differences were found in baseline characteristics. Pts who previously had been treated with anth-bch demonstrated significantly lower lvef than the other group and there were more patients with lvef in the normal lower limit. Gls was also lower but the difference was not significant. The fact that gls was not calculated in all patients may explain this finding. No differences were found in diastolic function. Previous cardiotoxic ttm and lower limit of normal lvef have been described as patient-related risk factors for developing cardiotoxicity. Currently, previous cardiotoxicity risk assessment is critical to allow preventive measures. Cardio-oncology units are crucial to address cardiovascular (cv) needs of cancer patients.